Page last updated: 2024-08-16

rivastigmine and Idiopathic Parkinson Disease

rivastigmine has been researched along with Idiopathic Parkinson Disease in 82 studies

Research

Studies (82)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	46 (56.10)	29.6817
2010's	27 (32.93)	24.3611
2020's	9 (10.98)	2.80

Authors

Authors	Studies
Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V	1
Bamford, A; Ben-Shlomo, Y; Emmett, SR; Gaunt, DM; Henderson, EJ; Hollingworth, W; Metcalfe, C; Neumann, S; Steeds, D; Taylor, J; Whone, A	1
Barr, PG; Rajkumar, AP; Storr, NJ; Watts, KE	1
Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA	1
Achten, E; Beun, S; Clement, P; Moyaert, P	1
Begemann, MJH; d'Angremont, E; Sommer, IEC; van Laar, T	1
Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A	1
Elango, DS; Espay, AJ; Gomez-Mancilla, B; Mahajan, A; Marsili, L; Masellis, M; Pathan, R; Pezous, N; Pilotto, A; Sturchio, A	1
Aldridge, GM; Anderson, SW; Narayanan, NS; Uc, EY; Zhang, Q	1
Bloem, BR; de Bie, RMA; de Haan, RJ; Foncke, EMJ; Munts, AG; Post, B; Schmand, BA; Tissingh, G; van Harten, B; van Mierlo, TJM	1
Ampil, E; Christopher, S; Kandiah, N; Karanam, AK; Looi, I; Pai, MC; Park, KW; Senanarong, V	1
Peall, KJ; Smith, MD	1
de Jong, IEM; Koshy Cherian, A; Kucinski, A; Sarter, M; Wu, R	1
Fine, EM; Guo, C; Johnson, ET; Kang, GA; Kramer, JH; Miller, BL; Possin, KL; Racine, CA; Seeley, WW; Trujillo, AJ; Wilheim, R; Witt, JL	1
Azulay, JP; Bordet, R; Defebvre, L; Defer, G; Delliaux, M; Destée, A; Devos, D; Duhamel, A; Dujardin, K; Eusebio, A; Kreisler, A; Krystkowiak, P; Lefaucheur, R; Maltête, D; Moreau, C; Ouk, T; Witjas, T	1
Ben-Shlomo, Y; Close, JC; Henderson, EJ; Lawrence, AD; Lord, SR; Whone, A	1
Braund, V; DesLauris, C; Leikin, JB	1
Chukhlovina, ML	1
Scicutella, A	1
Mamikonyan, E; Melvin, E; Weintraub, D; Xie, SX	1
Li, Z; Sun, C; Wang, J; Wang, P; Yu, Z; Zhang, J	1
Ransmayr, G	1
Lewis, SJ; Szeto, JY	1
Defebvre, L; Devos, D; Moreau, C	1
Ben-Shlomo, Y; Brodie, MA; Close, JC; Gaunt, DM; Henderson, EJ; Lawrence, AD; Lord, SR; Whone, AL	1
Amadori, K	1
Falkenburger, B	1
Saint-Hilaire, MH	1
Barone, P; Burn, DJ; Hsu, C; Lane, RM; Poewe, W; van Laar, T	1
Albanese, A; Lalli, S	1
Hasselbalch, SG; Kampmann, JP	1
Adler, CH; Almaraz, AC; Caselli, RJ; Caviness, JN; Demaerschalk, BM; Driver-Dunckley, ED; Wellik, KE; Wingerchuk, DM; Woodruff, BK	1
Chitnis, S; Rao, J	1
Darreh-Shori, T; Jelic, V	1
Aarsland, D; Brønnick, KS; Meng, X; Olin, JT; Schmitt, FA; Tekin, S	1
Aarsland, D; Meng, X; Olin, JT	1
Burr, O; Dannhardt, V; Oechsner, M; Pöhler, M; Reuter, I; Rosengarten, B; Rosengarten, S	1
Farlow, MR; Meng, X; Olin, JT; Schmitt, FA; Tekin, S	1
Deuschl, G; Förstl, H; Mollenhauer, B; Oertel, W; Storch, A; Trenkwalder, C	1
Landau, R	1
Meng, X; Somogyi, M; Weintraub, D	1
Bentivoglio, AR; Bove, F; Della Marca, G; Di Giacopo, R; Fasano, A; Quaranta, D	1
Fox, C; Maidment, I; McShane, R; Rolinski, M	1
Bullock, R; Cameron, A	1
Fogelson, N; Giladi, N; Kogan, E; Korczyn, AD; Neufeld, MY; Shabtai, H	1
Dautzenberg, PL; Oudejans, I; Samson, MM; Wouters, CJ	1
Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H	1
García-Borreguero, D; Serrano, C	1
Ludin, HP	1
Aarsland, D; Albanese, A; Byrne, EJ; De Deyn, PP; Deuschl, G; Durif, F; Emre, M; Kulisevsky, J; Lane, R; Lees, A; Poewe, W; Quarg, P; Robillard, A; Rosa, MM; Tekin, S; van Laar, T; Wolters, E	1
Press, DZ	1
Diraoui, S; Jansen, PA; van Melick, EJ	1
Boeve, BF	1
Harada, CN; Sachs, GA; Shega, JW	1
Cummings, JL	1
Morgan, J; Sethi, KD	1
Emre, M; Hsu, C; Lane, R; Onofrj, M; Poewe, W; Tekin, S; Wolters, E	1
Edgar, C; Emre, M; Lane, R; McKeith, I; Wesnes, KA	1
Boustani, M; Fox, C; Maidment, I	1
Blackhouse, G; Goeree, R; McBurney, C; Pullenayegum, EM; Willan, AR	1
Cummings, JL; Ringman, JM	1
Bernardini, S; Bonuccelli, U; Ceravolo, R; Frosini, D; Kiferle, L; Logi, C; Manca, G; Mariani, G; Murri, L; Rossi, C; Volterrani, D	1
Ballard, C; Barone, P; Ferrara, R; Lane, R; Tekin, S	1
Dautzenberg, PL; Rovers, JM; ter Bruggen, JP	1
Giladi, N; Gurevich, TY; Korczyn, AD; Shabtai, H; Simon, ES	1
Siddiqui, MA; Wagstaff, AJ	2
Aarsland, D; Burn, D; De Deyn, PP; Emre, M; Hsu, C; Lane, R; McKeith, I	1
Destée, A; Devos, D; Duhem, S; Dujardin, K; Durif, F; Lacomblez, L; Marié, RM; Péré, JJ; Pollak, P; Touchon, J	1
Johannsen, P	1
Mollenhauer, B; Trenkwalder, C; Wenzel, S	1
Aarsland, D; Brønnick, K; De Deyn, PP; Ehrt, U; Emre, M; Lane, R; Tekin, S	1
Antonello, RM; Moretti, R; Pizzolato, G; Torre, P; Vilotti, C	1
Damier, P; Meyniel, C	1
Wesnes, K	1
Cummings, JL; Emre, M; Lane, RM	1
Anghelescu, I; Heuser, I	1
Cummings, J; Winblad, B	1
Landmark, K; Reikvam, A	1
De Deyn, PP; Emre, M; Hsu, C; Kirsch, C; Lane, R; Oertel, W; Poewe, W; Tekin, S; Wolters, E	1
Luce, AK; McKeith, IG; Reading, PJ	1

Reviews

33 review(s) available for rivastigmine and Idiopathic Parkinson Disease

Article	Year
Multi-target-directed ligands to combat neurodegenerative diseases. Journal of medicinal chemistry, 2008, Feb-14, Volume: 51, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid	2008
Systematic review of pharmacological interventions for people with Lewy body dementia. Aging & mental health, 2023, Volume: 27, Issue:2 Topics: Alzheimer Disease; Dementia; Humans; Lewy Body Disease; Parkinson Disease; Rivastigmine	2023
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. The Cochrane database of systematic reviews, 2021, 02-03, Volume: 2 Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Memantine; Parkinson Disease; Quality of Life; Rivastigmine	2021
Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review. Journal of Alzheimer's disease : JAD, 2023, Volume: 93, Issue:4 Topics: Acetylcholinesterase; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Dementia; Galantamine; Humans; Indans; Parkinson Disease; Perfusion; Phenylcarbamates; Piperidines; Rivastigmine	2023
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA neurology, 2023, 08-01, Volume: 80, Issue:8 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Female; Hallucinations; Humans; Male; Parkinson Disease; Randomized Controlled Trials as Topic; Rivastigmine	2023
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. Drugs & aging, 2023, Volume: 40, Issue:11 Topics: Acetylcholinesterase; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Sleep Initiation and Maintenance Disorders	2023
Approach to Cognitive Impairment in Parkinson's Disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020, Volume: 17, Issue:4 Topics: Arousal; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Executive Function; Humans; Memory, Episodic; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Transcutaneous Electric Nerve Stimulation	2020
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clinical interventions in aging, 2017, Volume: 12 Topics: Acetylcholinesterase; Activities of Daily Living; Alzheimer Disease; Behavioral Symptoms; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Dementia; Dementia, Vascular; Humans; Parkinson Disease; Rivastigmine	2017
[Pathogenetic mechanisms of dementia in the older patients with Parkinson's diseases]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014, Volume: 114, Issue:7 Topics: Aging; alpha-Synuclein; Aminoquinolines; Cholinergic Neurons; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Male; Mutation; Parkinson Disease; Phenylcarbamates; Protein Kinases; Rivastigmine	2014
Cognitive impairment in Parkinson's disease. Psychiatria Danubina, 2015, Volume: 27, Issue:4 Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Memantine; Muscle Rigidity; Parkinson Disease; Risk Factors; Rivastigmine	2015
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. Current neuropharmacology, 2016, Volume: 14, Issue:4 Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Exercise Therapy; Galantamine; Humans; Indans; Memantine; Parkinson Disease; Piperidines; Rivastigmine; Sleep Wake Disorders; Treatment Outcome	2016
Parkinson's disease in the elderly. Medicine and health, Rhode Island, 2008, Volume: 91, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Comorbidity; Female; Health Status Indicators; Humans; Male; Parkinson Disease; Phenylcarbamates; Risk Factors; Rivastigmine	2008
Rivastigmine in Parkinson's disease dementia. Expert review of neurotherapeutics, 2008, Volume: 8, Issue:8 Topics: Brain; Cholinesterase Inhibitors; Dementia; Humans; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine	2008
Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. The neurologist, 2009, Volume: 15, Issue:4 Topics: Acetylcholine; Administration, Oral; Aged; Brain; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Humans; Lewy Body Disease; Male; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Placebos; Rivastigmine; Treatment Outcome	2009
Rivastigmine in Parkinson's disease dementia. Expert opinion on drug metabolism & toxicology, 2009, Volume: 5, Issue:8 Topics: Aged; Brain Chemistry; Dementia; Drug Approval; Humans; Middle Aged; Neuroprotective Agents; Parasympathetic Nervous System; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Risk Factors; Rivastigmine	2009
Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert opinion on drug safety, 2010, Volume: 9, Issue:1 Topics: Administration, Cutaneous; Administration, Oral; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dermatitis, Irritant; Humans; Nausea; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome; Vomiting	2010
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Deutsches Arzteblatt international, 2010, Volume: 107, Issue:39 Topics: Aged; Brain; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Diagnosis, Differential; Diagnostic Imaging; Donepezil; Early Diagnosis; Humans; Indans; Lewy Body Disease; Mental Disorders; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2010
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. The Cochrane database of systematic reviews, 2012, Mar-14, Issue:3 Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Lewy Body Disease; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2012
Fluctuations in cognition and alertness in Parkinson's disease and dementia. Neurology, 2004, Oct-26, Volume: 63, Issue:8 Suppl 3 Topics: Awareness; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Double-Blind Method; Humans; Lewy Body Disease; Melatonin; Multicenter Studies as Topic; Parkinson Disease; Phenylcarbamates; Phototherapy; Randomized Controlled Trials as Topic; Rivastigmine	2004
[Are there innovations in the treatment of Parkinson's disease?]. Praxis, 2004, Nov-03, Volume: 93, Issue:45 Topics: Antiparkinson Agents; Cannabis; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dopamine Agonists; Heart Valve Diseases; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pergolide; Phenylcarbamates; Placebos; Rivastigmine; Time Factors	2004
Cholinesterase inhibitors for Parkinson's disease dementia. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1 Topics: Cholinesterase Inhibitors; Dementia; Humans; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine	2006
Current and emerging pharmacological treatment options for dementia. Behavioural neurology, 2006, Volume: 17, Issue:1 Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine	2006
Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. International journal of clinical practice, 2006, Volume: 60, Issue:6 Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Double-Blind Method; Female; Heart Diseases; Humans; Lewy Body Disease; Male; Middle Aged; Multicenter Studies as Topic; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine	2006
Rivastigmine: in Parkinson's disease dementia. CNS drugs, 2006, Volume: 20, Issue:9 Topics: Animals; Cholinesterase Inhibitors; Dementia; Drug Evaluation; Humans; Parkinson Disease; Phenylcarbamates; Rivastigmine	2006
[Medical treatment of Alzheimer's disease]. Ugeskrift for laeger, 2006, Oct-02, Volume: 168, Issue:40 Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2006
[Diagnosis and clinical therapy for Parkinson's disease]. Der Nervenarzt, 2006, Volume: 77, Issue:12 Topics: Algorithms; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Humans; Mental Status Schedule; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine	2006
Rivastigmine in Parkinson's disease dementia: profile report. Drugs & aging, 2007, Volume: 24, Issue:3 Topics: Aged; Dementia; Humans; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine	2007
[Lewy body dementia and Parkinson disease dementia]. Presse medicale (Paris, France : 1983), 2007, Volume: 36, Issue:10 Pt 2 Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Dementia; Diagnosis, Differential; Disease Progression; Dopamine Agents; Humans; Iatrogenic Disease; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Parkinsonian Disorders; Phenylcarbamates; Psychotropic Drugs; Rivastigmine; Serotonin Antagonists	2007
Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:6 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Humans; Nausea; Parkinson Disease; Phenylcarbamates; Rivastigmine; Tremor; Vomiting	2007
Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. Journal of Alzheimer's disease : JAD, 2007, Volume: 11, Issue:4 Topics: Activities of Daily Living; Alzheimer Disease; Double-Blind Method; Hallucinations; Humans; Lewy Body Disease; Mental Status Schedule; Multicenter Studies as Topic; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2007
[Acetylcholinesterase inhibitors for dementia--an update]. MMW Fortschritte der Medizin, 2007, May-21, Volume: 149 Suppl 2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors	2007
A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert review of neurotherapeutics, 2007, Volume: 7, Issue:11 Topics: Alzheimer Disease; Dementia; Humans; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine	2007
Understanding changes in cholinergic function: implications for treating dementia. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:3 Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibitors; Dementia; Humans; Lewy Body Disease; Mental Disorders; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Treatment Outcome	2002

Trials

24 trial(s) available for rivastigmine and Idiopathic Parkinson Disease

Article	Year
Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease. BMC neurology, 2021, Oct-29, Volume: 21, Issue:1 Topics: Cholinesterase Inhibitors; Double-Blind Method; Gait Disorders, Neurologic; Humans; Parkinson Disease; Quality of Life; Rivastigmine	2021
Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up. Brain and behavior, 2021, Volume: 11, Issue:8 Topics: Cholinesterase Inhibitors; Follow-Up Studies; Hallucinations; Humans; Parkinson Disease; Phenylcarbamates; Rivastigmine	2021
Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. Journal of neurology, neurosurgery, and psychiatry, 2014, Volume: 85, Issue:6 Topics: Activities of Daily Living; Adult; Aged; Apathy; Cholinesterase Inhibitors; Dementia; Depression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index	2014
The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. BMC neurology, 2013, Dec-03, Volume: 13 Topics: Accidental Falls; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Male; Parkinson Disease; Phenylcarbamates; Quality of Life; Rivastigmine; Statistics, Nonparametric; Treatment Outcome	2013
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:7 Topics: Aged; Cholinesterase Inhibitors; Cognitive Dysfunction; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Rivastigmine	2015
Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients. European neurology, 2015, Volume: 74, Issue:1-2 Topics: Accidental Falls; Aged; Cholinesterase Inhibitors; Cognitive Dysfunction; Female; Humans; Male; Middle Aged; Parkinson Disease; Rivastigmine	2015
Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Neurology, 2016, Volume: 15, Issue:3 Topics: Accidental Falls; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Rivastigmine	2016
[Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling]. Zeitschrift fur Gerontologie und Geriatrie, 2016, Volume: 49, Issue:7 Topics: Accidental Falls; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Double-Blind Method; Female; Gait Disorders, Neurologic; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Placebo Effect; Rivastigmine; Treatment Outcome	2016
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Movement disorders : official journal of the Movement Disorder Society, 2008, Aug-15, Volume: 23, Issue:11 Topics: Aged; Analysis of Variance; Dementia; Double-Blind Method; Female; Homocysteine; Humans; Hyperhomocysteinemia; Male; Mental Status Schedule; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index	2008
Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dementia and geriatric cognitive disorders, 2010, Volume: 29, Issue:6 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenylcarbamates; Rivastigmine; Treatment Outcome	2010
Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS neuroscience & therapeutics, 2010, Volume: 16, Issue:6 Topics: Aged; Dementia; Double-Blind Method; Executive Function; Female; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Problem Solving; Reading; Rivastigmine; Thinking; Treatment Outcome	2010
Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:4 Topics: Aged; Cholinesterase Inhibitors; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Phenylcarbamates; Pilot Projects; Polysomnography; REM Sleep Behavior Disorder; Rivastigmine	2012
Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta neurologica Scandinavica, 2003, Volume: 107, Issue:4 Topics: Aged; Aged, 80 and over; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Dementia; Electroencephalography; Female; Humans; Male; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine	2003
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta neurologica Scandinavica, 2003, Volume: 108, Issue:5 Topics: Aged; Carbamates; Cholinesterase Inhibitors; Cognition; Dementia; Humans; Male; Parkinson Disease; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Time Factors; Treatment Outcome	2003
Rivastigmine for dementia associated with Parkinson's disease. The New England journal of medicine, 2004, Dec-09, Volume: 351, Issue:24 Topics: Aged; Cholinesterase Inhibitors; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Parkinson Disease; Phenylcarbamates; Rivastigmine; Tremor; Vomiting	2004
Rivastigmine for dementia associated with Parkinson's disease. Current neurology and neuroscience reports, 2005, Volume: 5, Issue:4 Topics: Aged; Cholinesterase Inhibitors; Dementia; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Disorders; Middle Aged; Nausea; Neuroprotective Agents; Parkinson Disease; Patient Selection; Phenylcarbamates; Prospective Studies; Rivastigmine; Treatment Outcome; Tremor; Vomiting	2005
Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:4 Topics: Activities of Daily Living; Aged; Cholinesterase Inhibitors; Cognition; Dementia; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Rivastigmine; Time Factors; Treatment Outcome	2006
Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology, 2005, Nov-22, Volume: 65, Issue:10 Topics: Aged; Aged, 80 and over; Attention; Cognition; Cognition Disorders; Corpus Striatum; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Frontal Lobe; Humans; Male; Middle Aged; Neural Pathways; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Placebos; Reaction Time; Rivastigmine; Treatment Outcome	2005
Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. Journal of neural transmission (Vienna, Austria : 1996), 2006, Volume: 113, Issue:11 Topics: Aged; Antiparkinson Agents; Brain; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; Image Processing, Computer-Assisted; Indans; Male; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tomography, Emission-Computed, Single-Photon	2006
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:11 Topics: Aged; Aged, 80 and over; Analysis of Variance; Cholinesterase Inhibitors; Dementia; Double-Blind Method; Female; Follow-Up Studies; Hallucinations; Humans; Male; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Prospective Studies; Rivastigmine; Treatment Outcome	2006
Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. Journal of neurology, 2006, Volume: 253, Issue:9 Topics: Aged; Dementia; Double-Blind Method; Female; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine	2006
Subthreshold depression in patients with Parkinson's disease and dementia--clinical and demographic correlates. International journal of geriatric psychiatry, 2007, Volume: 22, Issue:10 Topics: Age Factors; Age of Onset; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Depressive Disorder; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Psychomotor Disorders; Rivastigmine; Sex Factors	2007
Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug safety, 2008, Volume: 31, Issue:1 Topics: Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Psychomotor Performance; Remission, Spontaneous; Retrospective Studies; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome; Tremor	2008
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:6 Topics: Aged; Carbamates; Caregivers; Cognition Disorders; Female; Follow-Up Studies; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Stress, Psychological; Treatment Outcome	2001

Other Studies

25 other study(ies) available for rivastigmine and Idiopathic Parkinson Disease

Article	Year
Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Annals of neurology, 2021, Volume: 89, Issue:1 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Hypotension; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Rivastigmine	2021
Repurposed drugs for use in Parkinson's disease. Journal of neurology, 2018, Volume: 265, Issue:3 Topics: Double-Blind Method; Gait; Humans; Parkinson Disease; Rivastigmine	2018
Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease. Psychopharmacology, 2019, Volume: 236, Issue:6 Topics: Accidental Falls; Animals; Basal Forebrain; Benzylamines; Cholinesterase Inhibitors; Cognitive Dysfunction; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Female; Indoles; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rivastigmine; Serotonin Antagonists	2019
Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:10 Topics: Arousal; Attention; Cholinesterase Inhibitors; Cues; Executive Function; Female; Frontal Lobe; Functional Laterality; Head Movements; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Psychomotor Performance; Recovery of Function; Rivastigmine; Treatment Outcome	2013
Cholinergic symptoms with low serum cholinesterase from therapeutic cholinesterase inhibitor toxicity. The American journal of emergency medicine, 2014, Volume: 32, Issue:7 Topics: Aged; Bradycardia; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Humans; Indans; Lewy Body Disease; Male; Miosis; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine	2014
Rivastigmine treatment of Othello syndrome and post-ECT delirium in a patient with Parkinson's disease. The Journal of neuropsychiatry and clinical neurosciences, 2015,Winter, Volume: 27, Issue:1 Topics: Cholinesterase Inhibitors; Delirium; Electroconvulsive Therapy; Female; Humans; Middle Aged; Parkinson Disease; Phenylcarbamates; Rivastigmine; Schizophrenia, Paranoid	2015
Acetylcholinesterase inhibitors and gait: a steadying hand? The Lancet. Neurology, 2016, Volume: 15, Issue:3 Topics: Cholinesterase Inhibitors; Female; Gait Disorders, Neurologic; Humans; Male; Outcome Assessment, Health Care; Parkinson Disease; Rivastigmine	2016
ExPPNing how acetylcholine improves gait in Parkinson's disease: An Editorial Highlight for 'Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait'. Journal of neurochemistry, 2017, Volume: 140, Issue:5 Topics: Acetylcholine; Cholinergic Agents; Cholinesterase Inhibitors; Electric Stimulation; Gait Disorders, Neurologic; Humans; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rivastigmine; Subthalamic Nucleus; Tegmentum Mesencephali; Vesicular Acetylcholine Transport Proteins	2017
[Treatment of degenerative dementia disorders--who should be treated?]. Ugeskrift for laeger, 2009, Mar-02, Volume: 171, Issue:10 Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Dopamine Agents; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lewy Body Disease; Memantine; Middle Aged; Neuroprotective Agents; Parkinson Disease; Patient Selection; Phenylcarbamates; Rivastigmine	2009
Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. American journal of Alzheimer's disease and other dementias, 2010, Volume: 25, Issue:5 Topics: Cognition; Cognition Disorders; Dementia; Humans; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome	2010
Neurovascular coupling in Parkinson's disease patients: effects of dementia and acetylcholinesterase inhibitor treatment. Journal of Alzheimer's disease : JAD, 2010, Volume: 22, Issue:2 Topics: Aged; Aged, 80 and over; Case-Control Studies; Cerebral Arteries; Cholinesterase Inhibitors; Dementia; Electroencephalography; Evoked Potentials, Visual; Female; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Photic Stimulation; Rivastigmine; Ultrasonography, Doppler, Color	2010
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions: Evidence is not satisfactory. Deutsches Arzteblatt international, 2011, Volume: 108, Issue:8 Topics: Aged; Brain; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Diagnosis, Differential; Diagnostic Imaging; Donepezil; Early Diagnosis; Evidence-Based Medicine; Humans; Indans; Lewy Body Disease; Mental Disorders; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2011
Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. American journal of Alzheimer's disease and other dementias, 2011, Volume: 26, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Databases, Factual; Humans; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Retrospective Studies; Rivastigmine; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome	2011
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Current medical research and opinion, 2002, Volume: 18, Issue:5 Topics: Aged; Carbamates; Cholinesterase Inhibitors; Dementia; Female; Hallucinations; Humans; Male; Parkinson Disease; Phenylcarbamates; Rivastigmine; Treatment Outcome	2002
Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease. International journal of geriatric psychiatry, 2003, Volume: 18, Issue:6 Topics: Aged; Aortic Valve Insufficiency; Carbamates; Cholinesterase Inhibitors; Colitis, Ulcerative; Delirium; Humans; Male; Parkinson Disease; Phenylcarbamates; Postoperative Complications; Rivastigmine	2003
Parkinson's disease dementia--a first step? The New England journal of medicine, 2004, Dec-09, Volume: 351, Issue:24 Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Humans; Lewy Body Disease; Nausea; Parkinson Disease; Phenylcarbamates; Rivastigmine	2004
[Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease]. Nederlands tijdschrift voor geneeskunde, 2004, Nov-27, Volume: 148, Issue:48 Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Neuroprotective Agents; Olanzapine; Parkinson Disease; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Treatment Outcome	2004
Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease. The Lancet. Neurology, 2005, Volume: 4, Issue:3 Topics: Cholinesterase Inhibitors; Dementia; Humans; Lewy Body Disease; Parkinson Disease; Phenylcarbamates; Rivastigmine	2005
Rivastigmine for dementia associated with Parkinson's disease. The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13 Topics: Bias; Cholinesterase Inhibitors; Data Interpretation, Statistical; Dementia; Humans; Nausea; Parkinson Disease; Phenylcarbamates; Rivastigmine; Tremor; Vomiting	2005
Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:7 Topics: Cholinesterase Inhibitors; Comorbidity; Cross-Over Studies; Cross-Sectional Studies; Dementia; Donepezil; Double-Blind Method; Humans; Indans; Mental Status Schedule; Neuropsychological Tests; Outcome Assessment, Health Care; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2005
Economic evaluation of rivastigmine in patients with Parkinson's disease dementia. PharmacoEconomics, 2006, Volume: 24, Issue:1 Topics: Aged; Canada; Cost-Benefit Analysis; Dementia; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine	2006
[Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease]. Tijdschrift voor gerontologie en geriatrie, 2006, Volume: 37, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Female; Hallucinations; Humans; Male; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine; Treatment Outcome	2006
Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:10 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Drug Therapy, Combination; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status Schedule; Neurologic Examination; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine; Tremor	2006
Rivastigmine and Parkinson dementia complex. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:6 Topics: Cholinesterase Inhibitors; Dementia; Humans; Motor Activity; Parkinson Disease; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Treatment Outcome	2007
[Rivastigmine against dementia in Parkinson disease?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2007, Nov-15, Volume: 127, Issue:22 Topics: Cholinesterase Inhibitors; Dementia; Humans; Nausea; Parkinson Disease; Phenylcarbamates; Rivastigmine; Vomiting	2007